ValuEngine upgraded shares of Alliqua Biomedical (NASDAQ:ALQA) from a hold rating to a buy rating in a research report report published on Wednesday.
ALQA stock traded down $0.07 during mid-day trading on Wednesday, hitting $1.67. 644 shares of the company were exchanged, compared to its average volume of 25,779. The firm has a market cap of $8.51 million, a PE ratio of -0.26 and a beta of 1.25. Alliqua Biomedical has a 12-month low of $1.55 and a 12-month high of $2.78.
Alliqua Biomedical (NASDAQ:ALQA) last announced its earnings results on Friday, August 10th. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.64). The company had revenue of $0.86 million for the quarter. Alliqua Biomedical had a negative return on equity of 235.69% and a negative net margin of 90.48%. As a group, sell-side analysts anticipate that Alliqua Biomedical will post 5.14 EPS for the current fiscal year.
Alliqua Biomedical Company Profile
Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.
Recommended Story: What is a Reverse Stock Split?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.